<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Contraception: perimenopausal; Hormone replacement: surgery; Hormone replacement: oestrogens; HRT see Hormone replacement; Menopausal symptoms; Vaginitis: menopausal; Clonidine: menopausal flushing; Hormone replacement: risk table" /><meta name="IX" content="Contraception: perimenopausal; Hormone replacement: surgery; Hormone replacement: oestrogens; Menopausal symptoms; Vaginitis: menopausal; Clonidine: menopausal flushing; Hormone replacement: risk table" /><meta name="IXN" content="HRT see Hormone replacement" /><title>Hormone replacement therapy: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP4405-hormone-replacement-therapy.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP4405-hormone-replacement-therapy.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP4405-hormone-replacement-therapy.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP4031-endocrine-system.htm">6 Endocrine system</a> &gt; <a href="PHP4382-sex-hormones.htm">6.4 Sex hormones</a> &gt; <a href="PHP4383-female-sex-hormones-and-their-modulators.htm">6.4.1 Female sex hormones and their modulators</a> &gt; <a href="PHP4384-oestrogens-and-hrt.htm">6.4.1.1 Oestrogens and HRT</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP4384-oestrogens-and-hrt.htm" title="Previous: 6.4.1.1 Oestrogens and HRT">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP4420-oestrogens-for-hrt.htm" title="Next: OESTROGENS FOR HRT">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Hormone replacement therapy</h1><?highlighter on?><div id="pC" class="jN"><p>Hormone replacement therapy (HRT) with small doses of an oestrogen (together with a progestogen in women with a uterus) is appropriate for alleviating menopausal symptoms such as vaginal atrophy or vasomotor instability. Oestrogen given systemically in the perimenopausal and postmenopausal period or tibolone given in the postmenopausal period also diminish postmenopausal osteoporosis <a title="topic: Osteoporosis" href="PHP4643-osteoporosis.htm">(section 6.6.1)</a> but other drugs (<a title="section: Drugs affecting bone metabolism" href="PHP4642-drugs-affecting-bone-metabolism.htm">section 6.6</a>) are preferred. Menopausal atrophic vaginitis may respond to a short course of a topical vaginal oestrogen preparation <a title="sub-section: Preparations for vaginal atrophy" href="PHP4806-preparations-for-vaginal-and-vulval-changes.htm">(section 7.2.1) </a>used for a few weeks and repeated if necessary.</p><p>Systemic therapy with an oestrogen or drugs with oestrogenic properties alleviates the symptoms of oestrogen deficiency such as vasomotor symptoms. Tibolone combines oestrogenic and progestogenic activity with weak androgenic activity; it is given continuously, without cyclical progestogen.</p><p>HRT may be used in women with early natural or surgical menopause (before age 45 years), since they are at high risk of osteoporosis. For early menopause, HRT can be given until the approximate age of natural menopause (i.e. until age 50 years). Alternatives to HRT should be considered if osteoporosis is the main concern <a title="section: Drugs affecting bone metabolism" href="PHP4642-drugs-affecting-bone-metabolism.htm">(section 6.6)</a>.</p><p>Clonidine (<a title="monograph: CLONIDINE HYDROCHLORIDE" href="PHP1072-clonidine-hydrochloride.htm">section 2.5.2</a> and <a title="monograph: CLONIDINE HYDROCHLORIDE" href="PHP2885-clonidine-hydrochloride.htm">section 4.7.4.2</a>) may be used to reduce vasomotor symptoms in women who cannot take an oestrogen, but clonidine may cause unacceptable side-effects.</p><p>HRT increases the risk of venous thromboembolism, stroke, endometrial cancer (reduced by a progestogen), breast cancer, and ovarian cancer; there is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. For details of these risks see <a title="BNF:target-block: HRT Risk table" href="PHP4405-hormone-replacement-therapy.htm#PHP4409">HRT Risk table</a>.</p><p>The minimum effective dose of HRT should be used for the shortest duration. Treatment should be reviewed at least annually and for osteoporosis alternative treatments considered <a title="section: Drugs affecting bone metabolism" href="PHP4642-drugs-affecting-bone-metabolism.htm">(section 6.6)</a>. HRT does not prevent coronary heart disease or protect against a decline in cognitive function and it should <strong>not</strong> be prescribed for these purposes. Experience of treating women over 65 years with HRT is limited.</p><p>For the treatment of menopausal symptoms the benefits of short-term HRT outweigh the risks in the majority of women, especially in those aged under 60 years.</p> <div id="PHP4406"><h2>Risk of breast cancer</h2><p>It is estimated that using <em>all</em> types of HRT, including tibolone, increases the risk of breast cancer within 1–2 years of initiating treatment, see <a title="BNF:target-block: HRT Risk table" href="PHP4405-hormone-replacement-therapy.htm#PHP4409">HRT Risk table</a> for details. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping.</p><p>Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use; tibolone has only a limited effect on mammographic density.</p></div> <div id="PHP4407"><h2>Risk of endometrial cancer</h2><p>The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT, see <a title="BNF:target-block: HRT Risk table" href="PHP4405-hormone-replacement-therapy.htm#PHP4409">HRT Risk table</a> for details.</p><p>In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.</p></div> <div><h2>Risk of ovarian cancer</h2><p>Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer, see <a title="BNF:target-block: HRT Risk table" href="PHP4405-hormone-replacement-therapy.htm#PHP4409">HRT Risk table</a> for details; this excess risk disappears within a few years of stopping.</p></div> <div id="PHP4408"><h2>Risk of venous thromboembolism</h2><p>Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use, see <a title="BNF:target-block: HRT Risk table" href="PHP4405-hormone-replacement-therapy.htm#PHP4409">HRT Risk table</a> for details.</p><p>In<em> women who have predisposing factors</em> (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits. See below for advice on surgery.</p><p><em>Travel</em> involving prolonged immobility further increases the risk of deep vein thrombosis, see under Travel in <a title="target-block: Contraceptives -travel" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4871">section 7.3.1</a>.</p></div> <div><h2>Risk of stroke</h2><p>Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke. Tibolone increases the risk of stroke about 2.2 times from the first year of treatment, see <a title="BNF:target-block: HRT Risk table" href="PHP4405-hormone-replacement-therapy.htm#PHP4409">HRT Risk table</a> for details.</p></div><div><h2>Risk of coronary heart disease</h2><p>HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause, see <a title="BNF:target-block: HRT Risk table" href="PHP4405-hormone-replacement-therapy.htm#PHP4409">HRT Risk table</a> for details. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.</p></div> <div class="table" id="PHP4409"> <div class="cAA">HRT Risk<span></span></div> <table class="table" summary="HRT RiskHormone replacement: risk table" cellspacing="0" cellpadding="8" width="100%" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; border-left: 1pt solid ; border-right: 1pt solid ; "><colgroup><col /><col /><col /><col /><col /><col /><col /><col /></colgroup><thead><tr><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Risk</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Age range (years)</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " colspan="2">Background incidence per 1000 women in Europe not using HRT</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " colspan="2"><strong>Additional</strong> cases per 1000 women using <strong>oestrogen only HRT</strong> (estimated)</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " colspan="2"><strong>Additional</strong> cases per 1000 women using <strong>combined (oestrogen-progestogen) HRT</strong> (estimated)</th></tr><tr><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">Over 5 years</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">Over 10 years</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">For 5 years' use</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">For 10 years' use</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">For 5 years' use</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">For 10 years' use</th></tr></thead><tbody><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Breast cancer<cite><a href="PHP4405-hormone-replacement-therapy.htm#ID0EAILABIAA" class="tooltip ID0EAILABIAA">(1)</a></cite></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">10</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">20</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">24</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">15</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">30</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">9</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">9</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">36</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Endometrial cancer<cite><a href="PHP4405-hormone-replacement-therapy.htm#ID0EBJJABIAA" class="tooltip ID0EBJJABIAA">(2)</a></cite><cite><a href="PHP4405-hormone-replacement-therapy.htm#ID0EAJJABIAA" class="tooltip ID0EAJJABIAA">(3)</a></cite></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">4</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">4</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">32</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">48</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Ovarian cancer</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">4</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">&lt;1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">&lt;1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">1</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">&lt;1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">&lt;1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Venous thromboembolism<cite><a href="PHP4405-hormone-replacement-therapy.htm#ID0EBIFABIAA" class="tooltip ID0EBIFABIAA">(4)</a></cite><cite><a href="PHP4405-hormone-replacement-therapy.htm#ID0EAIFABIAA" class="tooltip ID0EAIFABIAA">(5)</a></cite></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">5</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">7</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">8</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">10</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Stroke<cite><a href="PHP4405-hormone-replacement-therapy.htm#ID0EAIDABIAA" class="tooltip ID0EAIDABIAA">(6)</a></cite></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">4</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">9</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">Coronary heart disease<cite><a href="PHP4405-hormone-replacement-therapy.htm#ID0EBHBABIAA" class="tooltip ID0EBHBABIAA">(7)</a></cite><cite><a href="PHP4405-hormone-replacement-therapy.htm#ID0EAHBABIAA" class="tooltip ID0EAHBABIAA">(8)</a></cite></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">70–79</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">29–44</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">15</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " colspan="8"><div class="cF"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">Where background incidence or additional cases have not been included in the table, this indicates a lack of available data. NS indicates a non-significant difference</p></div><p>Taken from MHRA/CHM (<em>Drug Safety Update</em> 2007; <strong>1</strong> (2): 2–6) available at <a href="http://www.mhra.gov.uk/drugsafetyupdate">www.mhra.gov.uk/drugsafetyupdate</a></p></div></td></tr></tbody></table> </div> <div id="PHP4411"><h2>Choice</h2><p>The choice of HRT for an individual depends on an overall balance of indication, risk, and convenience. A woman with a uterus normally requires oestrogen with cyclical progestogen for the last 12 to 14 days of the cycle <em>or</em> a preparation which involves continuous administration of an oestrogen and a progestogen (<em>or</em> one which provides both oestrogenic and progestogenic activity in a single preparation). Continuous combined preparations or tibolone are <strong>not suitable</strong> for use in the perimenopause or within 12 months of the last menstrual period; women who use such preparations may bleed irregularly in the early stages of treatment—if bleeding continues endometrial abnormality should be ruled out and consideration given to changing to cyclical HRT.</p><p>An oestrogen alone is suitable for continuous use in women without a uterus. However, in endometriosis, endometrial foci may remain despite hysterectomy and the addition of a progestogen should be considered in these circumstances.</p><p>An oestrogen may be given by mouth or by transdermal administration, which avoids first-pass metabolism. For the use of topical HRT preparations see <a title=" Preparations for vaginal atrophy" href="PHP4806-preparations-for-vaginal-and-vulval-changes.htm">section 7.2.1</a>.</p></div> <div><h2>Contraception</h2><p>HRT does <strong>not</strong> provide contraception and a woman is considered potentially fertile for 2 years after her last menstrual period if she is under 50 years, and for 1 year if she is over 50 years. A woman who is under 50 years and free of all risk factors for venous and arterial disease can use a low-oestrogen combined oral contraceptive pill (<a title=" Combined oral contraceptives" href="PHP4869-combined-hormonal-contraceptives.htm">section 7.3.1</a>) to provide both relief of menopausal symptoms and contraception; it is recommended that the oral contraceptive be stopped at 50 years of age since there are more suitable alternatives. If any potentially fertile woman needs HRT, non-hormonal contraceptive measures (such as condoms) are necessary.</p><p>Measurement of follicle-stimulating hormone can help to determine fertility, but high measurements alone (particularly in women aged under 50 years) do not necessarily preclude the possibility of becoming pregnant.</p></div> <div id="PHP4413"><h2>Surgery</h2><p>Major surgery under general anaesthesia, including orthopaedic and vascular leg surgery, is a predisposing factor for venous thromboembolism and it may be prudent to stop HRT 4–6 weeks before surgery (see Risk of Venous Thromboembolism, above); it should be restarted only after full mobilisation. If HRT is continued or if discontinuation is not possible (e.g. in non-elective surgery), prophylaxis with unfractionated or low molecular weight heparin and graduated compression hosiery is advised.</p></div> <div><h2>Reasons to stop HRT</h2><p>For circumstances in which HRT should be stopped, see <a title="target-block: hrt reasons to stop" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4878">section 7.3.1</a>.</p></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP4384-oestrogens-and-hrt.htm">Previous: 6.4.1.1 Oestrogens and HRT</a> | <a class="top" href="PHP4405-hormone-replacement-therapy.htm#">Top</a> | <a accesskey="]" href="PHP4420-oestrogens-for-hrt.htm">Next: OESTROGENS FOR HRT</a> ►</div><ol class="cC"><li class="footnote" id="ID0EAILABIAA"><p>Tibolone increases the risk of breast cancer but to a lesser extent than with combined HRT.</p></li><li class="footnote" id="ID0EBJJABIAA"><p>Evidence suggests an increased risk of endometrial cancer with tibolone. After 2.7 years of use (in women of average age 68 years), 1 extra case of endometrial hyperplasia and 4 extra cases of endometrial cancer were diagnosed compared with placebo users.</p></li><li class="footnote" id="ID0EAJJABIAA"><p>The risk of endometrial cancer cannot be reliably estimated in those using combined HRT because the addition of progestogen for at least 10 days per 28-day cycle greatly reduces the additional risk, and addition of a daily progestogen eliminates the additional risk. The risk of endometrial cancer in women who have not used HRT increases with body mass index (BMI); the increased risk of endometrial cancer in users of oestrogen-only HRT or tibolone is more apparent in women who are not overweight.</p></li><li class="footnote" id="ID0EBIFABIAA"><p>Limited data does not suggest an increased risk of thromboembolism with tibolone compared with combined HRT or women not taking HRT.</p></li><li class="footnote" id="ID0EAIFABIAA"><p>Although the level of risk of thromboembolism associated with non-oral routes of administration of HRT has not been established, it may be lower for the transdermal route.</p></li><li class="footnote" id="ID0EAIDABIAA"><p>Tibolone increases the risk of stroke about 2.2 times from the first year of treatment; risk of stroke is age-dependent and therefore the absolute risk of stroke with tibolone increases with age.</p></li><li class="footnote" id="ID0EBHBABIAA"><p>Increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause.</p></li><li class="footnote" id="ID0EAHBABIAA"><p>There is insufficient data to draw a conclusion on the risk of coronary heart disease with tibolone.</p></li></ol></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>